DSM Pharmaceutical Products appoints a new CEO and President.

Researchers from the University of Bradford, UK, have developed a solvent-free, continuous method to manufacture the more soluble and bioavailable form of artemisinin. The metastable form produced using high-temperature extrusion has been shown to have greater stability and longer shelf-life.

FDA publishes guidance on ANDA submissions.

EMA revises HIV treatment guideline.

The collaboration with Pfizer aims to develop next-generation, continuous manufacturing for solid-dosage pharmaceuticals.

Ablynx and AbbVie sign license agreement for Anti-IL-6R Nanobody, ALX-0061 to treat inflammatory diseases.

Cedarburg Hauser Pharmaceuticals has upgraded its API plant in Wisconsin.

Catalent Applied Drug Delivery Institute appoints Claus-Michael Lehr to advisory board.

West Pharmaceutical Services opens its second manufacturing plant in China to expand presence in Asian markets.

J&J's Janssen and PATH partner to improve drug formulation that could help prevent HIV infection.

ATMI has invested in sterile-connector and sterile-fill technology developed by Medical Instill Technologies.

Coldstream Laboratories partners with the National Cancer Institute for developing parental dosage forms for cancer drugs.

Sanofi?s plans strengthen its life-sciences presence at home in France and abroad in Africa.

Merck & Co. has received a Complete Response Letter from FDA for the resubmission of its new drug application for sugammadex sodium injection.

Covance launches external laboratory-management services for clinical trials.

Almac introduces a web-based tool for clinical-trial drug-supply management and refrigerated reusable shippers for clinical supplies.

Molecular Profiles has secured a major pan-European formulation project, in which the company will be responsible for developing a topical and an oral formulation for Telormedix's psoriasis products, TMX-302.

Use of a continuous-flow reaction made it possible to scale up a highly exothermic reaction for the production of a key Suzuki−Miyaura coupling reagent.

A global collaboration between AbbVie and Galapagos is set to commercialize novel potentiator and combination therapies in cystic fibrosis.

Boehringer Ingelheim initiates a recall due to the potential for extrinsic foreign particles in the API used to manufacture Spiriva Handihaler (tiotropium bromide inhalation powder) capsules.

GE Healthcare Life Sciences announced that it will build a KUBio modular biopharmaceutical factory in China for JHL Biotech.

Capsugel?s Dosage Form Solutions business unit will expand facilities in France, the UK, and the US.

AstraZeneca, Bristol-Myers Squibb recall certain lots of of their antidiabetes drug Bydureon (eventide) due to manufacturing records that batches may contain underfilled vials.

The CMDh agrees to suspend the marketing authorization of Numeta G13%E because of a risk of hypermagnesaemia.

The EMA Committee for CHMP recommends the approval of Xofigo in Europe.

CHMP recommended 11 new medicines for approval, the most approval recommendations at a CHMP meeting thus far in 2013.

CDC says antibiotic resistance is a quickly growing and dangerous problem.

Aesica Pharmaceuticals has built a new high-capacity manufacturing facility specifically for the production of solid dose medications used in the treatment of type II diabetes at its UK site in Queenborough, Kent.